Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression.

Zocchi L, Sassone-Corsi P.

Epigenetics. 2012 Jul;7(7):695-700. doi: 10.4161/epi.20733. Epub 2012 Jul 1.

2.

The ups and downs of BDNF in Rett syndrome.

Sun YE, Wu H.

Neuron. 2006 Feb 2;49(3):321-3. Review.

3.

Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?

Harrison IF, Dexter DT.

Pharmacol Ther. 2013 Oct;140(1):34-52. doi: 10.1016/j.pharmthera.2013.05.010. Epub 2013 May 24. Review.

PMID:
23711791
4.

Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS).

KhorshidAhmad T, Acosta C, Cortes C, Lakowski TM, Gangadaran S, Namaka M.

Mol Neurobiol. 2016 Mar;53(2):1092-107. doi: 10.1007/s12035-014-9074-1. Epub 2015 Jan 13. Review.

PMID:
25579386
5.

BDNF deregulation in Rett syndrome.

Li W, Pozzo-Miller L.

Neuropharmacology. 2014 Jan;76 Pt C:737-46. doi: 10.1016/j.neuropharm.2013.03.024. Epub 2013 Apr 15. Review.

6.

In sickness and in health: the role of methyl-CpG binding protein 2 in the central nervous system.

Díaz de León-Guerrero S, Pedraza-Alva G, Pérez-Martínez L.

Eur J Neurosci. 2011 May;33(9):1563-74. doi: 10.1111/j.1460-9568.2011.07658.x. Epub 2011 Apr 1. Review.

7.

Brain-derived neurotrophic factor and Rett syndrome.

Katz DM.

Handb Exp Pharmacol. 2014;220:481-95. doi: 10.1007/978-3-642-45106-5_18. Review.

PMID:
24668484
8.

The role of MeCP2 in the brain.

Guy J, Cheval H, Selfridge J, Bird A.

Annu Rev Cell Dev Biol. 2011;27:631-52. doi: 10.1146/annurev-cellbio-092910-154121. Epub 2011 Jun 29. Review.

PMID:
21721946
9.

Reading the unique DNA methylation landscape of the brain: Non-CpG methylation, hydroxymethylation, and MeCP2.

Kinde B, Gabel HW, Gilbert CS, Griffith EC, Greenberg ME.

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):6800-6. doi: 10.1073/pnas.1411269112. Epub 2015 Mar 4. Review.

10.

SIRT1 in neurodevelopment and brain senescence.

Herskovits AZ, Guarente L.

Neuron. 2014 Feb 5;81(3):471-83. doi: 10.1016/j.neuron.2014.01.028. Review.

11.

Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation.

Yu J, Auwerx J.

Pharmacol Res. 2010 Jul;62(1):35-41. doi: 10.1016/j.phrs.2009.12.006. Epub 2009 Dec 21. Review.

12.

How much successful are the medicinal chemists in modulation of SIRT1: A critical review.

Kumar A, Chauhan S.

Eur J Med Chem. 2016 Aug 25;119:45-69. doi: 10.1016/j.ejmech.2016.04.063. Epub 2016 Apr 27. Review.

PMID:
27153347
13.

The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.

Kong S, Yeung P, Fang D.

J Genet Genomics. 2013 Jul 20;40(7):347-54. doi: 10.1016/j.jgg.2013.04.001. Epub 2013 Apr 12. Review.

14.

Epigenetics and epilepsy.

Roopra A, Dingledine R, Hsieh J.

Epilepsia. 2012 Dec;53 Suppl 9:2-10. doi: 10.1111/epi.12030. Review.

15.

Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?

Zago V, Pinar-CabezaDeVaca C, Vincent JB, Ausio J.

Curr Top Med Chem. 2017;17(7):829-842. Review.

PMID:
27086783
16.

Role of mecp2 in experience-dependent epigenetic programming.

Zimmermann CA, Hoffmann A, Raabe F, Spengler D.

Genes (Basel). 2015 Mar 6;6(1):60-86. doi: 10.3390/genes6010060. Review.

17.

SIRT1 and Kidney Function.

Guan Y, Hao CM.

Kidney Dis (Basel). 2016 Mar;1(4):258-65. doi: 10.1159/000440967. Epub 2015 Oct 13. Review.

Supplemental Content

Support Center